Bayer Healthcare on Monday announced the launch of six new products that will be rolled out in Asia-Pacific over the next year and a half. The new products fall under the fields of ophthalmology, oncology and cardiology.
Among them is a product called EYLEA, which has been shown to improve sight to patients with wet Age-related Macular Degeneration (AMD), a disease that can lead to blindness.
With the new product, elderly patients who suffer from this disease can take their injection once every two months instead of once a month, according to Dr Chuan Kit Foo, Bayer Healthcare's Head of Medical Affairs in Asia-Pacific.
"It could potentially reduce the amount of hospital visits and allow patients to lead independent and better lives," said Dr Chuan referring to the new product.
Another product is Regorafenib, where tests have shown a 29 per cent increase in overall survival for patients with metastatic colorectal cancer.
Colorectal cancer is the most common cancer affecting men and second most common affecting women in Singapore.